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Diet and lifestyle produce major effects on tumour incidence, prevalence, and natural history. Moderate dietary restriction has
long been recognised as a natural therapy that improves health, promotes longevity, and reduces both the incidence and
growth of many tumour types. Dietary restriction differs from fasting or starvation by reducing total food and caloric intake
without causing nutritional deﬁciencies. No prior studies have evaluated the responsiveness of malignant brain cancer to
dietary restriction. We found that a moderate dietary restriction of 30–40% signiﬁcantly inhibited the intracerebral growth of
the CT-2A syngeneic malignant mouse astrocytoma by almost 80%. The total dietary intake for the ad libitum control group
(n=9) and the dietary restriction experimental group (n=10) was about 20 and 13 Kcal day
71, respectively. Overall health and
vitality was better in the dietary restriction-fed mice than in the ad libitum-fed mice. Tumour microvessel density (Factor VIII
immunostaining) was two-fold less in the dietary restriction mice than in the ad libitum mice, whereas the tumour apoptotic
index (TUNEL assay) was three-fold greater in the dietary restriction mice than in the ad libitum mice. CT-2A tumour cell-
induced vascularity was also less in the dietary restriction mice than in the ad libitum mice in the in vivo Matrigel plug assay.
These ﬁndings indicate that dietary restriction inhibited CT-2A growth by reducing angiogenesis and by enhancing apoptosis.
Dietary restriction may shift the tumour microenvironment from a proangiogenic to an antiangiogenic state through multiple
effects on the tumour cells and the tumour-associated host cells. Our data suggest that moderate dietary restriction may be
an effective antiangiogenic therapy for recurrent malignant brain cancers.
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About 35000 people in the United States are diagnosed each year
with primary or secondary brain tumours (Black, 1991). The prog-
nosis for many of these patients is poor despite new developments
in neurosurgery, chemotherapy, and radiotherapy (Shapiro, 1999).
Moreover, while the incidence of many cancers is decreasing, the
incidence of brain cancer is increasing in both children and the
elderly (Lowry et al, 1998; Kaiser, 1999; McKinley et al, 2000).
The highly inﬁltrative growth of malignant brain tumours and
difﬁculties in drug penetration of the neural parenchyma have
limited therapeutic options. Hence, there is a crucial need for
new and better brain tumour therapeutic strategies.
Several studies suggest that differences in diet and lifestyle can
have major effects on tumour incidence, prevalence, and natural
history (Blowers et al, 1997; Kaplan et al, 1997; Hu et al, 1999).
Dietary restriction (DR) has long been recognised as a natural ther-
apy that improves health, promotes longevity, and signiﬁcantly
reduces both the incidence and growth of many tumour types
(Rous, 1914; Tannenbaum, 1959; Weindruch and Walford, 1988;
Birt et al, 1999; Kritchevsky, 1999b). Dietary restriction differs
from severe fasting or starvation in that it reduces total caloric
or energy intake without causing deﬁciencies of any speciﬁc nutri-
ents (Tannenbaum, 1959; Mukherjee et al, 1999a). The mechanisms
by which DR reduces tumour growth are not yet clear, but likely
involve changes in tumour cells and in tumour associated host
cells.
Rous ﬁrst suggested that DR might inhibit tumour growth by
delaying host-mediated tumour vascularisation (Rous, 1914). Pili
et al (1994) and Mukherjee et al (1999a) later provided direct
support for Rous’ hypothesis by showing that DR was antiangio-
genic in experimental sarcomas and prostate tumours,
respectively. Moreover, the antiangiogenic effect of DR was
observed whether the calories were derived from fats or carbohy-
drates suggesting that tumour angiogenesis may be more
sensitive to reductions in the amount rather than in the type of
calories (Mukherjee et al, 1999a). Reduced total energy intake
through DR may inhibit tumour growth by shifting tumour-host
cell interactions from a proangiogenic to an antiangiogenic state.
Since neural tissues utilise glucose as the main energy substrate
(Clarke and Sokoloff, 1999), brain tumours may be responsive to
dietary and nutritional therapies. Moreover, the reliance of brain
tumours on glycolysis for energy should make them especially
vulnerable to DR, as DR shifts energy metabolism from glucose
to ketone utilisation (Oudard et al, 1997; Greene et al, 2001). With
the exception of an anecdotal report on the potential efﬁcacy of a
ketogenic diet toward paediatric astrocytoma (Nebeling et al,
1995), no studies have been performed to our knowledge on the
effects of DR as a therapeutic intervention for brain tumours. In
this study, we show for the ﬁrst time that moderate DR can inhibit
growth and vascularisation and enhance apoptosis in an orthotopic
mouse brain tumour model. A preliminary account of these ﬁnd-
ings has appeared (Mukherjee et al, 2001).
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Mice
Mice of the C57BL/6J strain and the BALBc/J-SCID (severe
combined immuno deﬁciency) strain were obtained from the Jack-
son laboratory (Bar Harbor, ME, USA). The mice were propagated
in the animal care facility of the department of Biology of Boston
College, using animal husbandry conditions described previously
(Flavin et al, 1991). Male mice (8–10 weeks of age ) were used
for the studies and were provided with food either ad libitum
(AL) or under restricted conditions (as below). Water was
provided AL to all mice. The animal room was maintained at
22+18C and cotton nesting pads were provided for additional
warmth. All animal experiments were carried out with ethical
committee approval in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and
were approved by the Institutional Care Committee. Also, these
procedures meet the standards required by the UKCCCR guidelines
(Workman et al, 1998).
Brain tumour model
The syngeneic CT-2A experimental mouse brain tumour used for
these studies was generated in our laboratory after implantation
of 20-methylcholanthrene into the cerebral cortex of a C57BL/6J
mouse according to the procedure of Zimmerman (Zimmerman
and Arnold, 1941; Seyfried et al, 1992). Histologically, the CT-2A
brain tumour is broadly classiﬁed as a poorly differentiated highly
malignant anaplastic astrocytoma (Seyfried et al, 1992). The
tumour grows orthotopically as a soft, noncohesive, and highly
vascularised mass.
Intracerebral tumour implantation
The CT-2A tumour was implanted into the cerebral cortex of
C57BL/6J mice using a trocar as we previously described (Seyfried
et al, 1987; Ranes et al, 2001). Brieﬂy, mice were anaesthetised
with pentobarbital (Vet Labs, Inc) intra-peritoneally and their
heads were shaved and swabbed with 70% ethyl alcohol under
sterile conditions. Small CT-2A tumour pieces (about 1 mm
3)
from a C57BL/6J donor mouse were implanted into the right
cerebral hemisphere of anaesthetised recipient mice as we recently
described (Ranes et al, 2001). All of the mice recovered from the
surgical procedure and were returned to their cages when fully
active. Initiation of tumours from intact tumour pieces is prefer-
able to initiation from cultured cells since the pieces already
contain an established microenvironment that facilitates tumour
growth.
Dietary restriction
The mice were group housed prior to the initiation of the experi-
ment and were then separated and randomly assigned to either a
control group that was fed AL or to an experimental group that
was fed a total DR of 30% (70% of the control group). Each mouse
was housed singly in a plastic shoe box cage with a ﬁlter top and
was given a cotton nesting pad for warmth. Dietary restriction was
initiated 7 days prior to tumour implantation and was continued
for either 11 or 14 days after implantation. Total DR maintains
a constant ratio of nutrients to energy, i.e., the average daily food
intake (grams) for the AL fed mice was determined every other day
and the DR-fed mice were given 70% of that quantity on a daily
basis (Mukherjee et al, 1999a). All mice received PROLAB chow
(Agaway Inc.), which contains a balance of mouse nutritional
ingredients and, according to the manufacturer’s speciﬁcation, deli-
vers 4.4 Kcal g
71 gross energy. Body weights of all mice were
recorded every other day.
Tumour growth
Intracerebral tumour growth was analysed directly by measuring
total tumour dry weight. Tumours were dissected from normal
appearing brain tissue, were frozen, and were then lyophilised to
remove water. From our experience, total tumour dry weight is a
more accurate measure of tumour growth than total wet weight
because individual CT-2A tumours can vary in the degree of
haemorrhage and oedema.
Histology
Tumour samples were ﬁxed in 10% neutral buffered formalin
(Sigma) and embedded in parafﬁn. Tumours were sectioned at
5 um, stained with haematoxylin and eosin, and examined by light
microscopy.
Factor VIII staining and microvessel quantitation
After deparafﬁnisation, rehydration, and washing, the tumour
sections were incubated with trypsin at 378C for 30 min as we
recently described for prostate tumours (Mukherjee et al, 1999a).
Brieﬂy, the sections were quenched with 0.3% H2O2-methanol
for 30 min and then blocked with 10% normal goat serum in
PBA buffer (100 ml of 0.01 M phosphate buffer with 0.9% sodium
chloride, and 1.0 g bovine serum albumin and 0.1 ml Tween 20,
pH 7.4). The sections were treated with rabbit polyclonal antibody
directed against human factor VIII-related antigen (Dako Corp.,
Carpinteria, CA, USA; 1:100 dilution with PBA) followed by a
biotinylated anti-rabbit IgG at 1:100 dilution (Vector Laboratories,
Inc., Burlingame, CA, USA). The sections were then treated with
avidin-biotin complex followed by 3-3' diaminobenzidine as
substrate for staining according to the manufacturer’s directions
(Vectastain Elite ABC kit ; Vector Laboratories, Inc.). The sections
were then rinsed three times with PBS (0.01 M phosphate buffer
with 0.9% NaCl). Sections were counter stained with methyl green
and mounted. Corresponding tissue sections without primary anti-
body served as negative controls. Microvessel density was
quantiﬁed by examining areas of vascular hotspots as previously
described by Weidner et al (1991) with some modiﬁcations.
Sections were scanned at low magniﬁcation (406 and 1006) for
the localisation of vascular hotspots. The three most vascular areas
of the tumour, not containing necrosis, were determined and then
counted at higher magniﬁcation (2006). The values of the three
sections were averaged and the results of three independent CT-
2A tumours were analyzed. Branching structures were counted as
a single vessel as previously shown (Mukherjee et al, 1999a).
In situ apoptotic cell detection (TUNEL)
Apoptotic cells were detected using the ApopTag in situ detection
kit TUNEL (terminal deoxynucleotidyl transferase mediated deox-
yuridine triphosphate biotin nick end labelling) (Oncor,
Gaithersberg, MD, USA) as we previously described (Mukherjee
et al, 1999a). After deparafﬁnisation, rehydration and washing in
PBS, the tissue sections were treated with proteinase K
(20 mgm l
71) for 15 min at room temperature and were then
washed in PBS. The sections were treated with 3% H2O2 in PBS
for 5 min to quench endogenous peroxide activities. The 3' hydro-
xy DNA strand breaks were enzymatically labelled with
digoxygeninnucleotide via TdT and incubated for 1 h at 378C.
The reaction was terminated with stop buffer according to the
manufacturer’s protocol. Sections were then treated with anti-
degoxygenin peroxidase for 30 min at room temperature, washed,
stained with 3-3' diaminobenzidine substrate, counter stained with
hematoxylin, and ﬁnally were mounted. Tissue sections of post
weaning normal female mouse mammary glands, provided by
Oncor, were used as a positive control and staining of a corre-
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control.
The apoptotic index was expressed as AI%=A6100/(A+C),
where A=TUNEL positive cells and C=counter stained unlabelled
cells. The tumour sections were scanned at lower magniﬁcation
(406 and 1006) for nonnecrotic areas and approximately 2000
total cells were counted for each section at higher magniﬁcation
(4006). The values of the three sections were averaged and the
results of three independent CT-2A tumours were analysed.
Proliferation index
Proliferation index measured the fraction of cells with proliferating
cell nuclear antigen (PCNA) staining as we previously described
(Mukherjee et al, 1999a). After deparafﬁnisation, rehydration and
washing, the tissue sections were soaked in 10 mM citrate buffer
(pH 6.0). The sections were heated in a microwave oven for
15 min (defrost cycle) and then cooled to room temperature to
unmask the PCNA. Sections were then stained by the same proce-
dures as described above except we used 10% horse serum as
blocking agent and PCNA mouse monoclonal antibody (Dako)
as the primary antibody. Light microscopy (4006) was used to
count both PCNA positive proliferating cells and total tumour cells
in three non necrotic areas of each tissue section as previously
shown (Mukherjee et al, 1999a).
In vivo Matrigel model of angiogenesis
Male BALB/c-SCID mice were divided into two groups of three
mice each: a control AL group and a 30% DR group. Dietary
restriction treatment was initiated 7 days prior to tumour cell
injection. CT-2A tumour cells were grown in culture and harvested
with 0.25% trypsin containing 1 mM EDTA. The cells were washed
twice, resuspended in serum free DMEM, and then thoroughly
mixed with Matrigel (Collaborative Biomedical) 1:2 (v v
71)a t
48C as we recently described (Manfredi et al, 1999). Mice were
anaesthetised with Isovet (Schering Plough Animal Health, Omaha,
NE, USA) and then injected with 1610
6 cells in 300 ml of Matrigel
subcutaneously in the dorsal midline using a prechilled tuberculin
syringe (27 gauge needle). The mice were maintained for another 7
days under the dietary regime at which time they were euthanised
and the Matrigel plug with the surrounding skin was removed as
we previously described (Manfredi et al, 1999). Vascularity was
photographed using a dissecting photomicroscope (Leica, WILD
macroskop).
RESULTS
No adverse effects were seen in the mice maintained on the 30–
40% DR. Despite a reduction in total body weight, the DR-fed
mice appeared healthy and were more active than the AL-fed mice
as assessed by ambulatory and grooming behaviour. No signs of
vitamin or mineral deﬁciency were observed in the DR-fed mice
according to standard criteria for mice (Hoag and Dickie, 1968).
These ﬁndings are consistent with the well-recognized health bene-
ﬁts of mild to moderate diet restriction in rodents (Weindruch and
Walford, 1988; Keenan et al, 1999).
Energy Intake
Our experimental design involved pretreatment with DR for 7 days
prior to intracerebral tumour implantation. This was done to sepa-
rate the physiological stress of single cage housing and food
restriction from surgical brain trauma. A slight reduction in energy
intake was noticed in both the AL-fed and the DR-fed mice at the
initiation of the experiment (Figure 1). This was attributed to the
effects of moving the mice from group housing to single cage
housing.
Energy intake increased signiﬁcantly in the AL-fed group about
2 days after intracerebral tumour implantation. This resulted from
a period of hyperphagia likely associated with cerebral hyperglyco-
lysis following the traumatic injury of tumour implantation
(Bergsneider et al, 1997). Energy intake was not increased in the
DR-fed mice to compensate for hyperphagia. Consequently, energy
intake was indirectly reduced in the DR-fed mice from 30% to
about 40% of that in the control AL-fed group. Hyperphagia asso-
ciated with orthotopic brain tumour growth is a novel ﬁnding and
was not observed in C57BL/6J mice with the CT-2A tumour grown
subcutaneously in ﬂank (Ranes et al, 2001).
The total energy intake of the AL-fed group was about 18 Kcal -
day
71, but rose to about 24 Kcal day
71 during the hyperphagic
period (Figure 1). The total energy intake of the DR-fed group
was adjusted to 13 Kcal day
71 during the 22 day experiment.
The DR-fed mice lost about 12% of their body weight during
the ﬁrst week of treatment and their weights remained signiﬁcantly
lower than those of the AL group throughout the study. The mean
(+s.e.m.) body weights (g) of the AL and DR mice after 17 days of
treatment were 23.6+0.6 and 20.3+0.4, respectively (P50.01, two
tailed t-test). Total energy intake and body weights dropped after
17 days in the AL-fed group due to increased tumour burden.
DR reduced intracerebral CT-2A tumour growth
Dry weights of the intracerebral CT-2A tumours were approxi-
mately 79.5% lower in the DR-fed mice than in the AL-fed mice
(Figure 2). It is important to mention that all implanted tumours
grew in both the AL and DR groups. These ﬁndings indicate that
DR did not prevent tumour take, but signiﬁcantly reduced intra-
cerebral growth of the malignant CT-2A brain tumour. We do
not think the reduced food intake beyond day 19 in the control
AL mice reduced the difference in tumor size between the AL
and CR mice.
Inﬂuence of DR on tumour vascularity, apoptosis, and cell
proliferation
We next examined tumour morphology and blood vessel densities
using H&E staining and Factor VIII immunostaining to determine
if DR inﬂuenced tumour angiogenesis. Three independent tumours
from the AL and DR groups were chosen at random for these
studies. The number and size of blood vessels and tumour cell
density were noticeably less in the DR-fed mice than in the AL-
fed mice (Figure 3A,B). Also, the tumour microvessel density of
the DR-fed mice was about half of that in the AL-fed mice (Figure
3C,D, and Table 1).
To determine if DR inﬂuenced programmed cell death (apopto-
sis) in the CT-2A tumour, we compared the number of TUNEL
positive cells (apoptotic index) in the AL-fed and DR-fed mice.
The apoptotic index was almost three-fold greater in the DR mice
than in the AL mice (Figure 3E,F and Table 1). No signiﬁcant
difference was found, however, between the DR and AL mice for
the PCNA proliferation index (Table 1), suggesting that the DR-
induced reduction of CT-2A growth was not associated with
reduced tumour cell proliferation.
DR reduced vascularity in the in vivo Matrigel model of
angiogenesis
The in vivo Matrigel angiogenesis model represents early events of
angiogenesis and tumour progression and is dependent on activa-
tion and inﬁltration of host stromal cells which include monocytes,
macrophages, and endothelial cell precursors (Manfredi et al,
1999). DR reduced vascularity when the CT-2A tumour cells were
grown in the in vivo Matrigel model of angiogenesis (Figure 4).
Although blood vessel quantitation is difﬁcult in the plugs, it is
clear from the ﬁgure that both the number and dilation of vessels
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than from the AL-fed mice. Similar qualitative differences were
seen in the other independent sample. These ﬁndings indicate that
DR reduces the angiogenic properties of the CT-2A tumour cells
whether grown within or outside of the central nervous system.
DISCUSSION
We found that a moderate DR of 30–40% signiﬁcantly reduced
angiogenesis and growth of the CT-2A experimental mouse astro-
cytoma. Moreover, DR enhanced CT-2A cell apoptosis without
effecting cell proliferation. Previous studies showed that moderate
DR could reduce the growth of histologically diverse non-neural
tumours (Rous, 1914; Tannenbaum, 1959; Kritchevsky, 1999a;
Mukherjee et al, 1999a). Our studies are the ﬁrst to document this
phenomenon in a brain tumour model and suggest that brain
tumours may be especially vulnerable to the growth-inhibitory
effects of DR. It will be important to document the extent to which
DR reduces angiogenesis and growth in other brain tumour
models.
Despite a 12% reduction in body weight, the DR-fed mice were
more active and healthy than the AL fed mice. Keenan and co-
workers recently suggested that the AL feeding of sedentary rodents
is a form of over feeding that can produce adverse health effects
(Keenan et al, 1999). Our results support this contention since
CT-2A tumour angiogenesis and growth was signiﬁcantly greater
in mice under AL feeding than under DR.
We found that angiogenic biomarkers may be useful for evalu-
ating the inﬂuence of energy intake and nutrition on the growth
and progression of experimental brain cancer. Moderate DR signif-
icantly reduced microvessel density, increased the apoptotic index,
but had little effect on the PCNA labelling index in the CT-2A
brain tumour. Other investigators have also reported that antian-
giogenic growth factors and cytokines can reduce tumour
microvessel density, increase apoptosis, but have little effect on cell
proliferation (Holmgren et al, 1995; O’Reilly et al, 1996; Tanaka et
al, 1997; Beecken et al, 2001). Our results therefore support
previous ﬁndings that DR produces a pattern of biomarker changes
similar to the changes seen following the implementation of anti-
angiogenic therapies (Mukherjee et al, 1999a; 1999b).
The mechanisms by which DR reduced CT-2A tumour angio-
genesis and growth are not yet clear, but may involve effects on
both the tumour cells and the tumour-associated host cells. It is
documented that human and experimental gliomas are dependent
on glycolysis for energy (Mies et al, 1990; Ikezaki et al, 1992;
Oudard et al, 1997), and that DR-induced caloric restriction
reduces glycolytic energy and down-regulates glycolytic gene
expression (Lee et al, 2000; Cao et al, 2001; Greene et al, 2001).
Additionally, the DR-induced down regulation of glycolysis should
also reduce the level of pyruvic acid, a glycolytic end product with
angiogenic activity (Lee et al, 2001).
Glucose is used exclusively for adult brain energy metabolism
under normal physiological conditions, but the brain will metabo-
lise ketone bodies for energy when blood glucose levels decrease as
during fasting or DR (Clarke and Sokoloff, 1999; Greene et al,
2001). Since ketone bodies are metabolised directly to acetyl-CoA
in the mitochondria, they bypass cytoplasmic glycolysis and
provide energy directly through the Krebs cycle (Nehlig and Pereira
de Vasconcelos, 1993; Clarke and Sokoloff, 1999). We recently
showed that DR produces ketosis in epileptic mice and that the
degree of ketosis is inversely proportional to blood glucose levels
(Greene et al, 2001). Further studies will be needed to determine
if reduced glycolytic energy and elevated ketosis underlie the anti-
angiogenic and growth inhibitory effects of DR.
In addition to possible effects on energy metabolism, DR may
also reduce CT-2A angiogenesis and growth through effects on
tumour associated host cells. The progression of human and
experimental brain tumours is dependent to a large extent on
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Figure 1 Energy intake in male C57BL6/J mice bearing the intracerebral
CT-2A brain tumour. DR was initiated on day 1 and tumours were im-
planted on day 8. Values are expressed as means+s.e.m. and n=the num-
ber of tumour-bearing mice examined in each group.
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Figure 2 Inﬂuence of DR on the intracerebral growth of the CT-2A
brain tumour. DR was initiated 7 days before tumour implantation and
was continued for 14 days after implantation as shown in Figure 1. Values
are expressed as means+s.e.m. and n=the number of tumour-bearing
mice examined in each group. The dry weight of the treated tumours
was signiﬁcantly lower than that of the control tumours (P50.001, two
tailed t-test).
Table 1 Effects of dietary restriction on microvessel density, apoptosis,
and proliferation index in the CT-2A brain tumour
Microvessel density
b Apoptotic Proliferation
Treatment
a vessels/high-power ﬁeld index %
c index %
d
AL 27.3+3.9 3.8+0.9 71.5+5.8
DR 13.0+2.0* 9.9+0.6** 69.7+4.9
aAnimals were fed either AL or under DR as described in Materials and Methods.
Three independent tumours chosen at random were analysed in each group and
all values are expressed as means+s.e.m. The asterisks indicate that the values from
the DR group differed from AL group at P50.05*, and P50.01** as determined by
the two tailed t-test. The details for each measurement are described in Materials and
Methods.
bFactor VIII-positive microvessels were averaged in three hotspot areas of
each tumour section at 2006.
cApoptotic index, determined from the TUNEL assay.
dProliferation index, determined from the PCNA assay.
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and macrophages (Seyfried, 2001). Indeed, the degree of tumour
angiogenesis and malignancy is generally correlated with the
number and activation state of tumour-associated macrophages
and microglia (Wood and Morantz, 1979; Roggendorf et al,
1996; Nishie et al, 1999; Polverini, 1999; Badie and Schartner,
2000). Recent studies also indicate that moderate DR reduces brain
inﬂammation associated with ageing and neurodegeneration (Duan
et al, 2001; Lee et al, 2000). Furthermore, dietary energy restriction
can elevate glucocorticoid hormone that could further reduce
tumour inﬂammation and growth through down regulation of
stress-activated protein kinase pathways (Birt et al, 1999). Hence,
DR may reduce CT-2A progression through a global down-regula-
tion of inﬂammatory and angiogenic properties of the tumour
microenvironment.
We also found that DR caused a noticeable reduction in the
number and the dilation of blood vessels in the in vivo Matrigel
model of angiogenesis indicating that DR can reduce angiogenesis
both within and outside of the central nervous system. It is possi-
ble that DR reduces the inﬂammatory properties of tumour-
associated host cells and thereby shifts tumour-host cell interac-
tions from a proangiogenic to an antiangiogenic state. Studies
are planned to test these possibilities.
Our ﬁndings may have relevance to those in vivo studies where
food intake and body weight are reduced in conjunction with
anticancer therapies or with cancer cachexia. Reduction of energy
intake as a covariable of anorexic anticancer therapies may
confound interpretation of results (Ranes et al, 2001). It would
be important therefore to control for the antitumour effects of
dietary reduction in the preclinical evaluation of new cancer drugs.
Weight loss associated with cancer cachexia differs from weight loss
associated with anorexia (reduction in food intake) since cachexia
can occur without anorexia and is produced from factors released
by the tumour (Tisdale, 2001). Although appearing counterintui-
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Figure 3 Inﬂuence of DR on microvessel density and apoptosis in the CT-2A brain tumour. DR was initiated 7 days before intracerebral tumour implanta-
tion and was continued for 11 days. H&E stained tumour sections in an AL mouse (A) and in a DR mouse (B) (1006). Factor VIII immunostaining from the
tumour grown in an AL mouse (C) and in a DR mouse (D) (2006). TUNEL positive apoptotic cells (arrows) from the tumour grown in an AL mouse (E)
and in a DR mouse (F) (4006). Each stained section was representative of the entire tumour. All images were produced from digital photography.
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tumour size and therby reducing levels of procachexic factors.
Although DR is recognised as a preventative measure for carci-
nogenisis, it is clear from our ﬁndings on the the CT-2A brain
tumour that DR is not a preventative intervention since all of
the tumours implanted grew despite the 7 day DR pretreatment
period. The DR-induced inhibition of CT-2A angiogenesis and
growth suggests that DR retards tumour progression. Whether
DR would also increase the survival time of CT-2A-tumour bearing
mice is not clear. Survival studies are difﬁcult with this rapidly
growing brain tumour model since the tumour will grow through
the implantation burr hole and then subcutaneously over the skull
as we previously described for the EPEN model (Seyfried et al,
1987). This relieves intracranial pressure and artiﬁcially extends
longevity. In humans with malignant brain tumours, it is the intra-
cranial pressure that usually leads to morbidity.
In summary, we have demonstrated that DR alone can reduce
angiogenesis and growth in an experimental mouse brain tumour.
Moreover, the antitumour action of DR likely operates through
multiple effects on the tumour cells and on the tumour associated
host cells. We contend that our experimental protocol may have
therapeutic potential for recurrent human gliomas since the time
of surgical tumour resection in humans would be comparable to
the time of tumour transplantation in mice. In other words, imple-
mentation of DR in the clinic could be most effective immediately
following tumour removal and may delay tumour recurrence.
Because DR is easy to administer and is devoid of adverse side
effects, our preclinical studies suggest that DR or caloric restriction
may have efﬁcacy as a non-invasive therapy for recurrent malignant
brain cancers.
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